CGS
vs
S
S&P/ASX 300
CGS
Over the past 12 months, CGS has significantly outperformed S&P/ASX 300, delivering a return of +71% compared to S&P/ASX 300's +1% growth.
Stocks Performance
CGS vs S&P/ASX 300
Performance Gap
CGS vs S&P/ASX 300
Performance By Year
CGS vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
CogState Ltd
Glance View
CogState Ltd makes digital cognitive tests and related software that measure memory, attention, and other brain functions. Its products are used in clinical trials, hospitals, research settings, and some routine care to help track brain health and detect changes over time. The company is not a drug maker; it sells assessment tools and services that help other organizations measure how well the brain is working. Its main customers are pharmaceutical and biotech companies running drug trials, along with researchers, clinics, and health systems that need standardized cognitive testing. CogState usually earns money by licensing its software, running testing programs, and providing study support and data services. That means customers pay for access to the tests, the platform behind them, and the work needed to set up and manage those assessments. What makes CogState different is that it sits at the measurement layer of brain health. Instead of treating diseases directly, it provides a repeatable way to collect cognitive data that can be used in drug development and patient monitoring. That gives the company a specialized role in a market where reliable, easy-to-administer brain testing is important but hard to do well at scale.
